title: Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients.
abstract: We have studied the effect of intravenous immunoglobulins (IVIG) on monocyte subpopulations and cytokine production in patients with CVID. The absolute number of CD14(+)CD16(++) monocytes decreased on average 2.5-fold 4h after IVIG and after 20h returned to the baseline. The cytokine level in the supernatants of peripheral blood mononuclear cells (PBMC) after ex vivo LPS stimulation demonstrated the >2-fold decrease in TNF production 4h after IVIG. The TNF expression, which is higher in the CD14(+)CD16(++) monocytes, was decreased in these cells by IVIG in 4/7 CVID cases. In vitro exposure of the healthy individuals' monocytes to the IVIG preparation resulted in reduced TNF production, which was overcome by blockade of the FcγRIIB in the CD14(+)CD16(++) CD32B(high) monocytes. Our data suggest that reduction in the number of CD14(+)CD16(++) monocytes and the blockade of their cytokine production via triggering CD32B can contribute to the anti-inflammatory action of IVIG.
authors.affiliation: Department of Clinical Immunology, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland. misiedla@cyf-kr.edu.pl
authors.forename: Maciej
authors.initials: M
authors.lastname: Siedlar
authors.forename: Magdalena
authors.initials: M
authors.lastname: Strach
authors.forename: Karolina
authors.initials: K
authors.lastname: Bukowska-Strakova
authors.forename: Marzena
authors.initials: M
authors.lastname: Lenart
authors.forename: Anna
authors.initials: A
authors.lastname: Szaflarska
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Węglarczyk
authors.forename: Magdalena
authors.initials: M
authors.lastname: Rutkowska
authors.forename: Monika
authors.initials: M
authors.lastname: Baj-Krzyworzeka
authors.forename: Anna
authors.initials: A
authors.lastname: Pituch-Noworolska
authors.forename: Danuta
authors.initials: D
authors.lastname: Kowalczyk
authors.forename: Tomasz
authors.initials: T
authors.lastname: Grodzicki
authors.forename: Loems
authors.initials: L
authors.lastname: Ziegler-Heitbrock
authors.forename: Marek
authors.initials: M
authors.lastname: Zembala
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000378:metabolism; D017074:Common Variable Immunodeficiency / Q000628:therapy*; D005260:Female; D058851:GPI-Linked Proteins / Q000378:metabolism; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use; D016130:Immunophenotyping; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D007700:Kinetics; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D017452:Receptors, IgG / Q000276:immunology / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C428200:FCGR3B protein, human; C080571:Fc gamma receptor IIB; D058851:GPI-Linked Proteins; D006684:HLA-DR Antigens; C508609:IL10 protein, human; D016756:Immunoglobulins, Intravenous; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12